Macrogenics Inc (MGNX) Stock: A Look at the Monthly Trend

19h ago, source: newsheater

In summary, Macrogenics Inc (MGNX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note ...

Buy Rating Affirmed for MacroGenics on Strong Oncology Pipeline and Positive Phase II Trial Results

1d ago, source:

Mayank Mamtani, an analyst from B.Riley Financial, has initiated a new Buy rating on MacroGenics (MGNX). Mayank Mamtani has given his Buy ...

MacroGenics, Inc. (MGNX)

1d ago, source: Yahoo Finance

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript March 7 ...

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

2mon ago, source: Stockhouse

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, ...

MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate

22d ago, source: Business Insider

Wednesday, MacroGenics Inc (NASDAQ:MGNX) provided an update on the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) for metastatic castration-resistant ...

Macrogenics Stock (NASDAQ:MGNX), Analyst Ratings, Price Targets, Predictions

18d ago, source: Benzinga.com

$16.94-17.36% HC Wainwright & Co.

MacroGenics, Inc. (MGNX)

3d ago, source: Yahoo Finance

Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data ...

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

23d ago, source: ADVFN

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of ...

Macrogenics Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...